VioQuest Pharmaceuticals, Inc. (VOQP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2007 | -6.61 Million USD | -25.34% |
| 2006 | -5.15 Million USD | 58.94% |
| 2005 | -10.35 Million USD | -258.22% |
| 2004 | -3.58 Million USD | -110.22% |
| 2003 | -1.7 Million USD | -681.11% |
| 2002 | -371.74 Thousand USD | -50.83% |
| 2001 | -144.06 Thousand USD | -34.72% |
| 2000 | -107.44 Thousand USD | -322.62% |
| 1999 | 48.28 Thousand USD | 334.83% |
| 1998 | 11.1 Thousand USD | 119.74% |
| 1997 | -56.26 Thousand USD | -3711.65% |
| 1996 | -1476.00 USD | -106.06% |
| 1995 | 24.36 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2008 Q1 | -1.66 Million USD | -59.47% |
| 2008 Q2 | -1.02 Million USD | 38.5% |
| 2007 Q4 | -1.04 Million USD | 50.4% |
| 2007 FY | - USD | -25.34% |
| 2007 Q3 | -2.1 Million USD | 1.57% |
| 2007 Q2 | -2.14 Million USD | 6.08% |
| 2007 Q1 | -2.28 Million USD | -14.17% |
| 2006 Q1 | -1.83 Million USD | 79.53% |
| 2006 FY | - USD | 58.94% |
| 2006 Q4 | -1.99 Million USD | -111.09% |
| 2006 Q3 | -946.1 Thousand USD | 45.66% |
| 2006 Q2 | -1.74 Million USD | 4.9% |
| 2005 Q3 | -1.36 Million USD | -34.89% |
| 2005 FY | - USD | -258.22% |
| 2005 Q2 | -1.01 Million USD | 14.2% |
| 2005 Q1 | -1.17 Million USD | 83.88% |
| 2005 Q4 | -8.94 Million USD | -555.61% |
| 2004 Q1 | -638.56 Thousand USD | -34.97% |
| 2004 FY | - USD | -110.22% |
| 2004 Q4 | -7.31 Million USD | -951.84% |
| 2004 Q3 | -694.99 Thousand USD | 39.92% |
| 2004 Q2 | -1.15 Million USD | -81.15% |
| 2003 FY | - USD | -681.11% |
| 2003 Q1 | -298.91 Thousand USD | -680.62% |
| 2003 Q3 | -442.15 Thousand USD | 10.11% |
| 2003 Q2 | -491.86 Thousand USD | -64.55% |
| 2003 Q4 | -473.1 Thousand USD | -7.0% |
| 2002 Q2 | -34.02 Thousand USD | 41.85% |
| 2002 FY | - USD | -50.83% |
| 2002 Q4 | -38.29 Thousand USD | -62.9% |
| 2002 Q3 | -32.23 Thousand USD | 59.18% |
| 2002 Q1 | -88.24 Thousand USD | -34.31% |
| 2001 Q2 | -15.32 Thousand USD | 28.15% |
| 2001 Q1 | -22.21 Thousand USD | 5.77% |
| 2001 Q4 | -73.71 Thousand USD | -124.44% |
| 2001 FY | - USD | -34.72% |
| 2001 Q3 | -32.81 Thousand USD | -105.54% |
| 2000 Q4 | -23.58 Thousand USD | 42.42% |
| 2000 Q3 | -40.98 Thousand USD | -379.1% |
| 2000 Q2 | -8558.00 USD | 75.07% |
| 2000 Q1 | -34.32 Thousand USD | 0.0% |
| 2000 FY | - USD | -322.62% |
| 1999 FY | - USD | 334.83% |
| 1998 FY | - USD | 119.74% |
| 1997 FY | - USD | -3711.65% |
| 1996 FY | - USD | -106.06% |
| 1995 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 90.693% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -11.513% |
| SQZ Biotechnologies Company | -64.14 Million USD | 89.692% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 61.937% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 107.031% |
| Mesoblast Limited | -62.38 Million USD | 89.403% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -330.424% |
| Genus plc | 73.7 Million USD | 108.971% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -86.398% |
| Marizyme, Inc. | -34.28 Million USD | 80.714% |
| ContraFect Corporation | -64.99 Million USD | 89.828% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 24.629% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -46.072% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -371.642% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -150.015% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -184.511% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1176.241% |
| Accustem Sciences Inc. | -3.74 Million USD | -76.476% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 86.291% |
| EV Biologics, Inc. | -1.26 Million USD | -421.77% |
| Q BioMed Inc. | -617.62 Thousand USD | -970.469% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 285.093% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -945.455% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -189.409% |
| Biomind Labs Inc. | -1.03 Million USD | -539.072% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 166.939% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 7.677% |
| Skye Bioscience, Inc. | -13.54 Million USD | 51.198% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -344.498% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -26346.068% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -70.21% |
| IMV Inc. | -35.52 Million USD | 81.388% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 58.339% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -164.253% |
| GB Sciences, Inc. | -1.41 Million USD | -365.637% |
| Alpha Cognition Inc. | -9.7 Million USD | 31.879% |
| HST Global, Inc. | -5303.00 USD | -124575.033% |
| CSL Limited | 4.78 Billion USD | 100.138% |
| Halberd Corporation | -74.27 Thousand USD | -8800.924% |
| Enzolytics Inc. | -2.12 Million USD | -211.566% |
| Resverlogix Corp. | -11.74 Million USD | 43.693% |
| Affymax, Inc. | -14.29 Million USD | 53.749% |
| SYBLEU INC | -141.57 Thousand USD | -4570.107% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -115.85% |
| argenx SE | -216.02 Million USD | 96.939% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 88.053% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 643.264% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -341.09% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1845.182% |
| AVAX Technologies, Inc. | -6.11 Million USD | -8.161% |
| Zenith Capital Corp. | -8.6 Million USD | 23.175% |
| Genscript Biotech Corporation | -248.71 Million USD | 97.342% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -37851.421% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -170.248% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -3656.024% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 83.32% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -128.588% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -531.888% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 98427.142% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -277.801% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -244.187% |
| BioStem Technologies, Inc. | -7.55 Million USD | 12.472% |
| ONE Bio Corp. | 13.61 Million USD | 148.568% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -3550.997% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -221.416% |
| Agentix Corp. | -1.37 Million USD | -381.975% |
| LadRx Corporation | 412.28 Thousand USD | 1703.636% |
| Cell Source, Inc. | -4.27 Million USD | -54.745% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1700.419% |
| Regen BioPharma, Inc. | 1.46 Million USD | 551.004% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -605.643% |
| NovAccess Global Inc. | -1.03 Million USD | -538.919% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 174.674% |
| Itoco Inc. | -1.86 Million USD | -253.747% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1641.615% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -492.43% |
| Kadimastem Ltd | -2.62 Million USD | -151.927% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -2664.59% |
| CytoDyn Inc. | -18.02 Million USD | 63.328% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -8265.938% |
| Mobile Lads Corp. | -2.24 Million USD | -195.004% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -53964.249% |
| Qrons Inc. | -40.08 Thousand USD | -16395.389% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1261.296% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1353.527% |
| Rebus Holdings, Inc. | -951 Thousand USD | -595.217% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -522.548% |
| International Stem Cell Corporation | 202 Thousand USD | 3373.028% |
| Bioxytran, Inc. | -3.82 Million USD | -73.07% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -12459.873% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -168.55% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 81.568% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -14592.26% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -141.472% |
| Neutra Corp. | -181.24 Thousand USD | -3547.794% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 67.203% |
| PureTech Health plc | -11.62 Million USD | 43.137% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 67.201% |
| IXICO plc | -707 Thousand USD | -835.151% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 13.969% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 86.325% |
| CSL Limited | 4.73 Billion USD | 100.14% |
| Cellectis S.A. | -92.63 Million USD | 92.863% |